<DOC>
	<DOC>NCT00956436</DOC>
	<brief_summary>This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.</brief_summary>
	<brief_title>Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥18 years Histologicallyconfirmed advanced HCC with at least 1 target lesion measurable by modified RECIST. ChildPugh score A5 or A6. ECOG Performance Status of ≤2. Known central nervous system or brain metastases. Prior antiIGF1R therapy. Prior systemic therapy for advanced HCC. Prior local therapies are only permitted if subjects have documented disease progression according to modified RECIST. Concurrent anticancer therapy. History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure. Acute hepatitis Fibrolamellar HCC Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>HCC</keyword>
	<keyword>BIIB022</keyword>
	<keyword>Open-Label</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Nexavar</keyword>
</DOC>